Sign Up to like & get
recommendations!
1
Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0929-z
Abstract: Sarilumab (Kevzara®), a monoclonal antibody against the interleukin-6 (IL-6) receptor, is approved in various countries, including the USA, those of the EU, and Japan, as a subcutaneous treatment administered every 2 weeks for moderately to severely…
read more here.
Keywords:
review moderate;
sarilumab review;
sarilumab;
rheumatoid arthritis ... See more keywords